Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

PALO ALTO, Calif.: PALO ALTO, Calif., Nov. 4, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today reported its third quarter 2021 financial results and provided a...

Click to view original post